Interstitial Pneumonitis Related to Pegylated Interferon Alfa-2a Treatment in a Patient with Chronic Hepatitis C.
作者信息
Alkan Erhan, Akin Mete, Adanir Haydar, Tuna Yasar
机构信息
Department of Gastroenterology, Burdur State Hospital, Burdur, Turkey.
Department of Gastroenterology, Akdeniz University School of Medicine, Antalya, Turkey.
出版信息
Euroasian J Hepatogastroenterol. 2016 Jan-Jun;6(1):91-92. doi: 10.5005/jp-journals-10018-1176. Epub 2016 Jul 9.
Abstract
Alkan E, Akin M, Adanir H, Tuna Y. Interstitial Pneumonitis Related to Pegylated Interferon Alfa-2a Treatment in a Patient with Chronic Hepatitis C. Euroasian J Hepato-Gastroenterol 2016;6(1):91-92.
摘要
相似文献
1
Interstitial Pneumonitis Related to Pegylated Interferon Alfa-2a Treatment in a Patient with Chronic Hepatitis C.
Euroasian J Hepatogastroenterol. 2016 Jan-Jun;6(1):91-92. doi: 10.5005/jp-journals-10018-1176. Epub 2016 Jul 9.
2
Interstitial pneumonitis associated with pegylated interferon-alpha 2a and ribavirin for chronic hepatitis C infection: a case report.
Cases J. 2009 Mar 10;2:6464. doi: 10.1186/1757-1626-0002-0000006464.
3
Surfactant protein-D is more useful than Krebs von den Lungen 6 as a marker for the early diagnosis of interstitial pneumonitis during pegylated interferon treatment for chronic hepatitis C.
Hepatogastroenterology. 2012 Oct;59(119):2260-3. doi: 10.5754/hge10868.
4
[Importance of adherence for efficacy of hepatitis C combined therapy].
Srp Arh Celok Lek. 2013 Jul-Aug;141(7-8):507-10.
5
Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial.
Lancet Gastroenterol Hepatol. 2017 Dec;2(12):877-889. doi: 10.1016/S2468-1253(17)30288-1. Epub 2017 Sep 28.
6
Pegylated interferons for the treatment of chronic hepatitis C infection.
Clin Ther. 2002 Sep;24(9):1363-83. doi: 10.1016/s0149-2918(02)80042-x.
8
Pegylated interferon plus ribavirin for the treatment of chronic hepatitis C.
Rev Gastroenterol Disord. 2003 Spring;3(2):93-109.
9
[HBsAg loss with Pegylated-interferon alfa-2a in hepatitis B patients with partial response to nucleos(t)-ide analog: new switch study].
Zhonghua Gan Zang Bing Za Zhi. 2018 Oct 20;26(10):756-764. doi: 10.3760/cma.j.issn.1007-3418.2018.10.005.
10
Pegylated interferons for chronic hepatitis C virus infection: an indirect analysis of randomized trials.
J Viral Hepat. 2008 Aug;15(8):551-70. doi: 10.1111/j.1365-2893.2008.00984.x. Epub 2008 May 14.
本文引用的文献
1
Interstitial pneumonitis associated with pegylated interferon-alpha 2a and ribavirin for chronic hepatitis C infection: a case report.
Cases J. 2009 Mar 10;2:6464. doi: 10.1186/1757-1626-0002-0000006464.
2
Pneumonitis as a consequence of (peg)interferon-ribavirin combination therapy for hepatitis C: a review of the literature.
Dig Dis Sci. 2010 Mar;55(3):579-85. doi: 10.1007/s10620-009-0797-1. Epub 2009 Apr 28.
3
Spectrum of pulmonary toxicity associated with the use of interferon therapy for hepatitis C: case report and review of the literature.
Clin Infect Dis. 2004 Dec 1;39(11):1724-9. doi: 10.1086/425746. Epub 2004 Nov 8.
4
Side effects of therapy of hepatitis C and their management.
Hepatology. 2002 Nov;36(5 Suppl 1):S237-44. doi: 10.1053/jhep.2002.36810.
5
Significant pulmonary toxicity associated with interferon and ribavirin therapy for hepatitis C.
Am J Gastroenterol. 2002 Sep;97(9):2432-40. doi: 10.1111/j.1572-0241.2002.05999.x.
6
Pneumonitis during interferon and/or herbal drug therapy in patients with chronic active hepatitis.
Eur Respir J. 1996 Dec;9(12):2691-6. doi: 10.1183/09031936.96.09122691.
7
Side effects of high-dose interferon therapy for chronic hepatitis C.
J Hepatol. 1996 Sep;25(3):283-91. doi: 10.1016/s0168-8278(96)80113-9.
Zotero 插件